Synthetic Biologics (SYN) Reports Third-Party Analysis of Trimesta Phase 2 Data; Results Not Statistically Significant
Tweet Send to a Friend
Synthetic Biologics, Inc. (NYSE: SYN) reported independent third party analysis of the investigator-sponsored Phase 2 clinical trial that evaluated Trimesta ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
